Dr. Osama Ibrahim is a highly-experienced Principal Research Scientist with particular expertise in the field of microbiology, molecular biology, food safety, and bioprocessing for both pharmaceutical and food ingredients. He is knowledgeable in microbial screening /culture improvement; molecular biology and fermentation research for antibiotics, enzymes, therapeutic proteins, organic acids and food flavors, biochemistry for metabolic pathways , enzymes kinetics, enzymes immobilization, bioconversion, and analytical biochemistry. Dr. Ibrahim was external research liaison for Kraft Foods with Universities for research projects related to molecular biology and microbial screening. He holds several bioprocessing patents and publications. Read more
Dr. Osama Ibrahim is a highly-experienced Principal Research Scientist with particular expertise in the field of microbiology, molecular biology, food safety, and bioprocessing for both pharmaceutical and food ingredients. He is knowledgeable in microbial screening /culture improvement; molecular biology and fermentation research for antibiotics, enzymes, therapeutic proteins, organic acids and food flavors, biochemistry for metabolic pathways , enzymes kinetics, enzymes immobilization, bioconversion, and analytical biochemistry. Dr. Ibrahim was external research liaison for Kraft Foods with Universities for research projects related to molecular biology and microbial screening. He holds several bioprocessing patents and publications. In January 2005, he retired from Kraft Foods Reseach Center and formed his own biotechnology company (Bio Innovation) providing technical and marketing consultation for new startup biotechnology and food companies.
Dr. Ibrahim received his B.S. in Agricultural Biochemistry with honor and two M.S. degrees in Microbial physiology/ Fermentation and in Applied Microbiology. He received his Ph.D in Basic Medical Science (Microbiology, Immunology and Molecular biology) from New York Medical College. His research dissertation was on the construction of plasmid for the expression of a fusion protein of Vascular endothelial growth factor / Shiga-like toxin ( VEGF121 / SLT) as a therapeutic protein for targeting angiogenesis (cancer treatment). He is a member of American Chemical Society, American Society of Microbiology, and Society of Industrial Microbiology .
